Considerations for treatment duration in responders to immune checkpoint inhibitors
Open accessThe DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“long-term PD-1 blockade predisposes patients to a higher risk of irAEs and increased financial burden without a proven effect on outcomes129.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Cited by
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00224-8 · Cited by 421
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationImmune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC: CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 205
Managing Metastatic Melanoma in 2022: A Clinical Review
Switzer, B., Puzanov, I., Skitzki, J. J., Hamad, L., & Ernstoff, M. S. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00686 · Cited by 190
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 116
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Malmberg, R., Zietse, M., Dumoulin, D. W., Hendrikx, J. J. M. A., Aerts, J. G. J. V., van der Veldt, A. A. M., Koch, B. C. P., Sleijfer, S., & van Leeuwen, R. W. F. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00554-x · Cited by 105
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Bauer, A. T., Gorzelanny, C., Gebhardt, C., Pantel, K., & Schneider, S. W. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102322 · Cited by 103
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 102
Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses
Dosil, S. G., López‐Cobo, S., Rodríguez‐Galán, A., Fernández‐Delgado, I., Ramírez‐Huesca, M., Milán-Rois, P., Castellanos, M., Somoza, Á., Gómez, M. J., Reyburn, H. T., et al. (2022) · eLife · doi:10.7554/elife.76319 · Cited by 94
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z. S., Saba, N. F., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02568-y · Cited by 78
Current Insights and Progress in the Clinical Management of Head and Neck Cancer
Amaral, M., Faísca, P., Ferreira, H. A., Gaspar, M. M., & Reis, C. P. (2022) · Cancers · doi:10.3390/cancers14246079 · Cited by 76
Rizvi, N. A., Ademuyiwa, F. O., Cao, Z. A., Chen, H. X., Ferris, R. L., Goldberg, S. B., Hellmann, M. D., Mehra, R., Rhee, I. P., Park, J. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005920 · Cited by 61
What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
Yin, J., Song, Y., Tang, J., & Zhang, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983581 · Cited by 44
Sun, L., Cohen, R. B., D’Avella, C. A., Singh, A. P., Schoenfeld, J. D., & Hanna, G. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.28526 · Cited by 44
Atkins, M. B., Ascierto, P. A., Feltquate, D., Gulley, J. L., Johnson, D. B., Khushalani, N. I., Sosman, J. A., Yap, T. A., Kluger, H. M., Sullivan, R. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005923 · Cited by 31
Checkpoint Inhibitor-Induced Colitis: An Update
Losurdo, G., Angelillo, D., Favia, N., Sergi, M. C., Leo, A. D., Triggiano, G., & Tucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051496 · Cited by 30
Dent, J., Jorge, M., Sobrevilla, N., Uldrick, T. S., Adoubi, I., Bajpai, J., Burotto, M., Bulhan, H., Dosunmu, G. T., Ekpo, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011258 · Cited by 29
Wahli, M. N., Hayoz, S., Hoch, D., Ryser, C. O., Hoffmann, M., Scherz, A., Schwacha-Eipper, B., Haefliger, S., Wampfler, J., Berger, M. D., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04309-2 · Cited by 29
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Machairas, N., Tsilimigras, D. I., & Pawlik, T. M. (2022) · Cancers · doi:10.3390/cancers14082018 · Cited by 27
Disis, M. L., Adams, S. F., Bajpai, J., Butler, M. O., Curiel, T. J., Dodt, S. A., Doherty, L., Emens, L. A., Friedman, C. F., Gatti-Mays, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006624 · Cited by 27
Dummer, R., Corrie, P. G., Gutzmer, R., Meniawy, T. M., Vecchio, M. D., Lebbé, C., Guida, M., Dutriaux, C., Dréno, B., Meyer, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02199 · Cited by 27
Ghorani, E., Quartagno, M., Blackhall, F. H., Gilbert, D. C., O'Brien, M. E. R., Ottensmeier, C. H. H., Pizzo, E., Spicer, J. F., Williams, A., Badman, P. D., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00095-5 · Cited by 26
Bogani, G., Cinquini, M., Signorelli, D., Pizzutilo, E. G., Romanò, R., Bersanelli, M., Raggi, D., Alfieri, S., Buti, S., Bertolini, F., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104016 · Cited by 25
Valentin, J., Ferté, T., Dorizy-Vuong, V., Dousset, L., Prey, S., Dutriaux, C., Pham‐Ledard, A., Beylot-Barry, M., & Gerard, É. (2021) · Journal of Oncology · doi:10.1155/2021/5524685 · Cited by 25
Sandbank, E., Eckerling, A., Margalit, A., Sorski, L., & Ben‐Eliyahu, S. (2023) · Current Oncology · doi:10.3390/curroncol30080540 · Cited by 24
Jang, A., Lanka, S. M., Jaeger, E., Lieberman, A., Huang, M., Sartor, O. A., Mendiratta, P., Brown, J. R., Garcia, J. A., Farmer, T. E., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00131 · Cited by 24
Pelicon, V., Čufer, T., & Knez, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1182748 · Cited by 24
Prospects of POLD1 in Human Cancers: A Review
Gola, M., Stefaniak, P., Godlewski, J., Jereczek‐Fossa, B. A., & Starzyńska, A. (2023) · Cancers · doi:10.3390/cancers15061905 · Cited by 23
Radiotherapy and Immunotherapy in Lung Cancer
Hsieh, K., Dickstein, D. R., Runnels, J., Lehrer, E. J., Rosenzweig, K. E., Hirsch, F. R., & Samstein, R. M. (2023) · Biomedicines · doi:10.3390/biomedicines11061642 · Cited by 23
Chen, Z., Chen, J., Huang, D., Zhang, W., Wu, L., Yi, T., Wang, Q., Han, L., Tan, L., Li, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02115-5 · Cited by 22
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma
Basu, A., Au, C., Kommalapati, A., Kandala, H., Sudhaman, S., Mahmood, T., Carson, C., Pajak, N., Dutta, P., Calhoun, M. A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00667 · Cited by 22
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 21
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 20
Pala, L., Pagan, E., Sala, I., Oriecuia, C., Oliari, M., Pas, T. M. D., Specchia, C., Cocorocchio, E., Zattarin, E., Rossi, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102681 · Cited by 20
Zhou, S., Sun, Y., Chen, T., Wang, J., He, J., Lyu, J., Shen, Y., Chen, X., & Yang, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739594 · Cited by 20
Bryant, A. K., Chopra, Z., Edwards, D. M., Whalley, A. S., Bazzell, B. G., Moeller, J. A., Kelley, M. J., Fendrick, A. M., Kerr, E. A., Ramnath, N., et al. (2023) · Health Affairs · doi:10.1377/hlthaff.2023.00102 · Cited by 19
Tachiki, L. M. L., Hippe, D. S., Silva, K. W., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A. M., Majovski, J., Pulliam, T. H., Goldstein, D. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03539-8 · Cited by 19
Chatziioannou, E., Leiter, U., Thomas, I., Keim, U., Seeber, O., Meiwes, A., Boessenecker, I., Gonzalez, S. S., Meraz-Torres, F., Niessner, H., et al. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00775-7 · Cited by 19
Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
Papp, K. A., Puig, L., Beecker, J. R., Chandran, V., Claveau, J., Cortés, J., Dutz, J. P., Hornick, N. I., Juergens, R. A., Melosky, B. L., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20809 · Cited by 18
Stukalin, I., Navani, V., Gupta, M., Ruan, Y., Boyne, D. J., O'Sullivan, D. E., Meyers, D. E., Goutam, S., Sander, M., Ewanchuk, B. W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad073 · Cited by 17
Ellebæk, E., Schina, A., Andersen, R. S., Hendel, H. W., Svane, I. M., & Donia, M. (2022) · International Journal of Cancer · doi:10.1002/ijc.33926 · Cited by 17
Lievense, L. A., Heukels, P., van Walree, N. C., & van der Leest, C. H. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100441 · Cited by 16
Gupta, M., Stukalin, I., Meyers, D. E., Goutam, S., Heng, D. Y. C., Cheng, T., Monzon, J. G., & Navani, V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.19607 · Cited by 16
Mallardo, D., Sparano, F., Vitale, M. G., Trojaniello, C., Fordellone, M., Cioli, E., Esposito, A., Festino, L., Mallardo, M., Vanella, V., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03728-z · Cited by 16
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
Kuah, C. Y., Monfries, R., Quartagno, M., Seckl, M. J., & Ghorani, E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231210271 · Cited by 15
Survival after cessation of immunotherapies in melanoma: A systematic review and meta‐analysis
Mayer, K. E., Warburton, L., Zaremba, A., Preis, S., Foerster, Y., Biedermann, T., & Persa, O. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20672 · Cited by 13
Hara, T., Furukawa, J., Shiraishi, Y., Okamura, Y., Bando, Y., Terakawa, T., Harada, K., Nakano, Y., & Fujisawa, M. (2023) · International Journal of Urology · doi:10.1111/iju.15193 · Cited by 13
Tang, Z., Zha, L., Liang, R., & Li, T. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01778-7 · Cited by 12
Ru, L., & Zheng, J. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2024-0086 · Cited by 12
Yuan, Q., Xu, C., Wang, W., & Zhang, Q. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241246651 · Cited by 12
Lewis, R. I., Seuthe, K., Lennartz, S., Weber, J.-P., Kreuzberg, N., Klingel, K., & Bröckelmann, P. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1328378 · Cited by 12
Ito, K., Kita, Y., Yokomizo, A., Miki, J., Yoshio, Y., Matsumoto, H., Segawa, T., Karashima, T., Nishiyama, N., Imai, K., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5057 · Cited by 12
Role of cytoreductive surgery in the era of immunotherapy
Isali, I., Braun, A. E., Bukavina, L., & Psutka, S. P. (2022) · Current Opinion in Urology · doi:10.1097/mou.0000000000001037 · Cited by 12
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00449-3 · Cited by 11
Al-Awadhi, A. M., Alnaqbi, S., & Albawardi, A. S. (2024) · Cureus · doi:10.7759/cureus.53419 · Cited by 10
T-cell immunotherapy for melanoma
Rosa, C. M. D., Vancheswaran, A., & Ariyan, C. E. (2024) · Surgical Oncology · doi:10.1016/j.suronc.2024.102160 · Cited by 10
Inoue, Y., Kitahara, Y., Karayama, M., Asada, K., Nishimoto, K., Matsuura, S., Hashimoto, D., Fujii, M., Matsui, T., Inami, N., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100847 · Cited by 10
Zhang, J., Venchiarutti, R. L., Wang, X., & He, Q. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03030-4 · Cited by 9
Self-citationLiu, J., 叶婷, Zhang, X. F., Dong, Y., Zhang, W., Wu, F., Bo, H., Shao, H., Zhang, R., & Shen, H. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022067 · Cited by 9
Shan, W., Zhu, J., & Shen, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090087 · Cited by 8
Financial burden of high-cost immunotherapy among cancer survivors in Medicare
Owsley, K. M., & Bradley, C. J. (2025) · Journal of Cancer Survivorship · doi:10.1007/s11764-025-01797-2 · Cited by 8
Optimising oncology drug expenditure in Ireland
Kieran, R., Hennessy, M., Coakley, K. E., O’Sullivan, H., Cronin, T., Lynch, D., Mulroe, E., Cooke, K., Collins, D. C., & O’Reilly, S. (2024) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-024-03672-y · Cited by 8
Elective Checkpoint Inhibitor Discontinuation in Metastatic Solid Tumor Patients: A Case Series
Lopez-Flores, R., Samlowski-, W., & Perez, L. (2022) · Annals of Case Reports · doi:10.29011/2574-7754.100894 · Cited by 8
Yao, Y., Liu, Z., Li, Q., Cao, B., & Wang, M. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14279 · Cited by 8
Fujikawa, M., Tajiri, T., Takemura, M., Nakao, K., Yamamoto, S., Takeda, N., Fukumitsu, K., Fukuda, S., Kamemitsu, Y., Uemura, T., et al. (2022) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2022.101720 · Cited by 7
Immune checkpoint inhibitors in non-small cell lung cancer – When should we dare to stop treatment?
Bozorgmehr, F., Müller, A. M., Rawluk, J. K., Sianidou, M., Chung, I., & Kropf-Sanchen, C. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107340 · Cited by 7
Therapeutic Efficacy of Nanocarrier‐Mediated Inhalable Gene Transfection for Lung Cancer
Sarkar, P., Sardar, M., Sen, O., Das, S., & Manna, S. (2024) · ChemistrySelect · doi:10.1002/slct.202402903 · Cited by 6
Pandey, T., & Bhatti, S. A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04143-8 · Cited by 6
Pedersen, S., Byrdal, M., Martinenaite, E., Lorentzen, C. L., Kjeldsen, J. W., Thorsen, S. U., Kverneland, A. H., Zocca, M.-B., Andersen, M. H., & Svane, I. M. (2025) · Nature Communications · doi:10.1038/s41467-025-67508-8 · Cited by 6
Foo, T., Krishnan, T., Tebbutt, N. C., Price, T. J., Karapetis, C. S., & Roy, A. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2708761 · Cited by 6
Kaur, S., Awad, D., Finney, R. P., Meyer, T. J., SINGH, S. P., Cam, M. C., Karim, B. O., Warner, A., & Roberts, D. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032612 · Cited by 5
Optimizing the doses of cancer drugs after usual dose finding
Strohbehn, G. W., Stadler, W. M., Boonstra, P. S., & Ratain, M. J. (2023) · Clinical Trials · doi:10.1177/17407745231213882 · Cited by 5
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer
Morganti, S., & Tolaney, S. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.014 · Cited by 5
Gross, N. D., & Seiwert, T. Y. (2024) · Cancer · doi:10.1002/cncr.35198 · Cited by 5
Kuusisalo, S., Iivanainen, S., & Koivunen, J. P. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2476729 · Cited by 5
Lu, Z., Afzal, M. Z., & Shirai, K. (2023) · Transplant Immunology · doi:10.1016/j.trim.2023.101932 · Cited by 5
Ornstein, M. C., George, L. L., Wei, W., Diaz-Montero, C. M., Rayman, P. A., Martin, A. M., Basu, A., Beckermann, K. E., Nizam, A., Wee, C. E., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102181 · Cited by 5
Smith, H. G., Bodilsen, A., Rose, L., Altaf, R., Iversen, L. H., & Walker, L. R. (2023) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2023.108286 · Cited by 5
Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?
Namikawa, K., Nakano, E., Ogata, D., & Yamazaki, N. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17147 · Cited by 4
Schuurbiers, M. M. F., van Delft, F. A., Koffijberg, H., IJzerman, M. J., Monkhorst, K., Ligtenberg, M. J. L., van den Broek, D., van Rossum, H. H., & van den Heuvel, M. M. (2025) · Tumor Biology · doi:10.1177/14230380251316788 · Cited by 4
Sharma, H., Moturi, K., Pankratz, V. S., Yilmaz, E., Gbolahan, O. B., Kumar, A., & Hashemi‐Sadraei, N. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04812-0 · Cited by 4
Hietala, A., Joutsen, J., Vaarala, S., & Säily, M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-246653 · Cited by 4
Wolf, J. M., & Xu, Y. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101244 · Cited by 4
Sun, Z. X., Li, Y., Ma, H., Gao, Y., Hu, J., & Zheng, L. (2026) · Science Progress · doi:10.1177/00368504261456476 · Cited by 3
Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinoma
Chuang, C.-H., Chen, C.-T., Hsu, C., & Shao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04052-w · Cited by 3
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Tomsitz, D., Livingstone, E., Loquai, C., Kaatz, M., Leiter, U., Schilling, B., Terheyden, P. A. M., Hassel, J. C., Sachse, M., Ulrich, J., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20650 · Cited by 3
Lee, A. S., Valero, C., Yoo, S., Vos, J. L., Chowell, D., & Morris, L. G. T. (2023) · Cancers · doi:10.3390/cancers16010175 · Cited by 3
Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
Wang, S., Tian, B., & Wang, H. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s482456 · Cited by 3
Berclaz, L. M., Burkhard‐Meier, A., Lechner, A., Völkl, M., Güler, S. E., Abdel-Rahman, S., Mansoorian, S., Kunz, W. G., Knösel, T., Canis, M., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04029-9 · Cited by 3
Cabezas-Camarero, S., Iglesias-Moreno, M. C., Druet, E. C., Sotelo, M. J., Merino‐Menéndez, S., Cabrera‐Martín, M. N., Plaza-Hernández, J. C., & Pérez‐Segura, P. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001422 · Cited by 3
Ma, X., Ou, K., Liu, X., Cao, B., Yang, W., Lu, J., Zhang, L., Wang, Q., Gao, L., Jiang, Z., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70299 · Cited by 2
Czarnecka, A. M., Teterycz, P., Ostaszewski, K., Błoński, P. J., Zielińska, M., Galus, Ł., Dziura, R., Kempa-Kamińska, N., Galwas, K., Cybulska-Stopa, B., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01156-2 · Cited by 2
Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity
Cánovas‐Cervera, I., Nácher-Sendra, E., Suay, G., Lahoz, A., García‐Giménez, J. L., & Mena, S. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.002 · Cited by 2
Improving assessment of financial toxicity of cancer immunotherapy
Liu, J., Lustberg, M. B., & Sonis, S. T. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09796-w · Cited by 2
The unexplored mechanism of antitumoral effect of pirfenidone in melanoma cells
Marchese, M., Regina, G. L., Amato, R., Bertoni, G., Ruzzolini, J., Martinucci, D., Papucci, L., Peppicelli, S., & Bianchini, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-13584-1 · Cited by 2
Birkmire, J., Haslam, A., Hernandez, E. F., & Olivier, T. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115701 · Cited by 2
Mathematical Analysis and Simulations of a Cancer Model With Interleukins and Delayed Immunotherapy
Boudjellal, L., Soares, A. J., & Torres, M. J. (2026) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.70757 · Cited by 2
Allurkar, S., Patadiya, H. H., Dental Practice, M. D. S., Marmat, H., Kundu, D., Tulsi, S. P. S., & Gupta, S. P. (2025) · Bioinformation · doi:10.6026/973206300210044 · Cited by 2
Metadata
- Authors
- Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., Olson, D., Naqash, A. R., Patel, R. B., Sachdev, E., Rodriguez-Ruiz, M. E., Sheffer, M., Church, S., Fuhrman, C., Overacre-Delgoffe, A., Nguyen, R., Florou, V., Thaxton, J. E., Aggen, D. H., & Guerriero, J. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- National University of Ireland (IE)
- The University of Texas Southwestern Medical Center (US)
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- Hummingbird Scientific (United States) (US)
- Johns Hopkins University (US)
- Vanderbilt University (US)
- Moffitt Cancer Center (US)
- University of Washington (US)
- University of Chicago (US)
- University of Pittsburgh (US)
- University of Southern California (US)
- Clinica Universidad de Navarra (ES)
- Dana-Farber Cancer Institute (US)
- Transitional Sciences, NanoString Technologies Inc, Seattle, Washington, USA
- Nanostring Technologies (United States) (US)
- National Cancer Institute (US)
- Huntsman Cancer Institute (US)
- Medical University of South Carolina (US)
- Memorial Sloan Kettering Cancer Center (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Guerriero, Jennifer L
- ORCID
- Marron, Thomas U
- Ryan, Aideen E
- Reddy, Sangeetha M
- Kaczanowska, Sabina
- Younis, Rania H
- Thakkar, Dipti
- Zhang, Jiajia
- Bartkowiak, Todd
- Howard, Rachel
- Anderson, Kristin G
- Olson, Daniel
- Naqash, Abdul Rafeh
- Patel, Ravi B
- Rodriguez-Ruiz, Maria E
- Sheffer, Michal
- Fuhrman, Christopher
- Overacre-Delgoffe, Abigail
- Nguyen, Rosa
- Florou, Vaia
- Thaxton, Jessica E
- Aggen, David H
- Guerriero, Jennifer L
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-03
- Volume
- 9
- Issue
- 3
- Pages
- e001901
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7929825
- OpenAlex
- W3134221665
- Cited by
- 137
- References
- 49
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 21 · 2023: 36 · 2022: 31 · 2021: 5
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- SITC SPARKATHON
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- immune checkpoint inhibitors, treatment duration, durable response, overtreatment, financial toxicity, health-related quality of life, treatment response biomarkers, early clinical trials, metastatic melanoma, immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Clinical Trials as Topic, Drug Administration Schedule, Humans, Neoplasms, Risk Factors, Time Factors, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.